Cost-effectiveness analysis of febuxostat in patients with gout in Spain

References

• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheumatism 2004;51:321-5
   PubMed Web of Science ®Google Scholar
• Spanish Society of Rheumatology (SER). Clinical practice guidelines for management of gout. Madrid, Spain: Spanish Society of Rheumatology (SER), 2013. www.ser.es/practicaClinica/Guias_practica_clinica/Guias_finalizadas.php. Accessed April 20, 2015
   Google Scholar
• Vazquez-Mellado J, Alvarez Hernandez E, Burgos-Vargas R. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol 2004;18:111-24
   PubMed Web of Science ®Google Scholar
• Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002;14:281-6
   PubMed Web of Science ®Google Scholar
• Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-26
   PubMed Web of Science ®Google Scholar
• Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593-617
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21
   PubMed Web of Science ®Google Scholar
• Smith EU, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010;24:811-27
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Saag KG. New insights into gout epidemiology. Curr Opin Rheumatol 2006;18:199-203
   PubMed Web of Science ®Google Scholar
• Carmona L. Epidemiología de las enfermedades reumáticas. Manual SER de las enfermedades reumáticas. 4th edn. Madrid: Editorial Panamericana, 2004
   Google Scholar
• Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: The Gout Evaluation and Management Study. J Clin Rheumatol 2011;17:349-55
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Final appraisal determination. Febuxostat for the management of hyperuricaemia in people with gout. NICE, 2008. London (UK). https://www.nice.org.uk/guidance/ta164. Accessed April 20, 2015
   Google Scholar
• Scottish Medicines Consortium (SMC). Febuxostat 80 mg and 120 mg Tablets (Adenuric) SMC No. 637/10. 2010. Glasgow (UK). http://www.scottishmedicines.org.uk/files/advice/febuxostat-Adenuric-FINAL-August-2010.pdf. Accessed April 20, 2015
   Google Scholar
• Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ 2014;15:453-63
   PubMed Web of Science ®Google Scholar
• Schumacher HR, Jr., Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
   PubMed Web of Science ®Google Scholar
• Lopez Bastida J, Oliva J, Antoñanzas F, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit 2010;24:154-70. Spanish
   PubMed Web of Science ®Google Scholar
• Puig-Junoy J, Oliva-Moreno J, Trapero-Bertrán M, et al. Guía y recomendaciones para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut. Generalitat de Catalunya. Barcelona: Departament de Salut. Servei Català de la Salut, 2014
   Google Scholar
• Perez-Ruiz F, Martinez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-82
   PubMed Web of Science ®Google Scholar
• Becker MA, MacDonald P, Chefo S, et al. Baseline (BL) characteristics of gout subjects influence Urate-Lowering (UL) efficacy during febuxostat and allopurinol treatment [abstract]. Arthritis Rheum 2009;60(10 Suppl):704
   Google Scholar
• Schumacher HR, Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-94
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24
   PubMed Web of Science ®Google Scholar
• Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis J Rheumatol 2004;31:2429-32
   PubMed Web of Science ®Google Scholar
• Institute of Medical Science World Publications Ltd. A health economic assessment of febuxostat in the management of gout. Data on File. Version No. 1.0. 2007. London (UK)
   Google Scholar
• General Council of the Association of Official Pharmacists. General Council of the Association of Official Pharmacists Database: Bot PLUS 2.0. Madrid (Spain). https://botplusweb.portalfarma.com/. Accessed April 22, 2015
   Google Scholar
• Royal Decree-Law 8/2010. Extraordinary measures to reduce the public deficit. Amended by the Royal Decree-Law 9/2011. Madrid (Spain). http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf. Accessed April 2015
   Google Scholar
• Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J. Resource use and economic impact of patients with gout: a multicenter, population-wide study. Reumatol Clin 2013;9:94-100
   PubMedGoogle Scholar
• Gisbert R, Brosa M. Healthcare cost database eSALUD [Internet]. Barcelona: Oblikue Consulting, 2015. www.oblikue.com. Accessed April 20, 2015
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del Llano J, et al. What is an efficient health technology in Spain? Gac Sanit 2002;16:334-43
   PubMedGoogle Scholar
• Brook RA, Kleinman NL, Patel PA, et al. The economic burden of gout on an employed population Curr Med Res Opin 2006;22:1381-9
   PubMed Web of Science ®Google Scholar
• Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 2012;10:117
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology 2007;46:1441-4
   PubMed Web of Science ®Google Scholar
• Ipsen UK. Febuxostat for the treatment of gout: single technology appraisal submission to the National Institute for Health and Clinical Excellence. 2008. London (UK). http://www.nice.org.uk/guidance/ta164/documents/manufacturer-ipsen-submission2. Accessed January 2015
   Google Scholar
• Redding L, Hornberger J, Cowens W, et al. Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada. Poster presented at: Canadian Agency for Drugs and Technologies in Health Symposium; April 3-5, 2011; Vancouver, British Columbia, Canada. https://www.cadth.ca/poster-presentations-0. Accessed April 2015
   Google Scholar
• Meltzer M, Pizzi LT, Jutkowitz E. Payer decision-making with limited comparative and cost-effectiveness data: the case of new pharmacological treatments for gout. Evid Based Med 2012;17:105-8
   PubMedGoogle Scholar
• Jutkowitz E, Choi HK, Pizzi LT, et al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med 2014;161:617-26
   PubMed Web of Science ®Google Scholar
• Smolen LJ, Wielage RC, Gahn JC, et al. The cost-effectiveness of Febuxostat in the management of patients with gout. J Manag Care Pharm 2014;20(4-a Suppl):S52. M18EM [Abstract]. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=17840. Accessed April 20, 2015
   Google Scholar
• Gandhi PK, Gentry WM, Ma Q, et al. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm 2015;21:165-75
   PubMed Web of Science ®Google Scholar
• Khanna PP, Perez-Ruiz F, Maranian P, et al. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011;50:740-5
   PubMed Web of Science ®Google Scholar
• Spaetgens B, Wijnands JM, van Durme C, et al. Cost of illness and determinants of costs among patients with gout. J Rheumatol 2015;42:335-44
   PubMed Web of Science ®Google Scholar